NT1-O12B is an endogenous chemical and a neurotransmitter-derived lipoid (NT-lipidoid) that is an effective carrier for enhanced intrabrain transport of several BBB (blood-brain barrier) non-permeable (penetrable) substances. . Doping NT1-O12B into BBB-impermeable (penetrable) lipid nanoparticles (LNPs) can give LNPs the ability to cross the BBB. NT liposomes are not only beneficial to the transmembrane transport of BBB, but also can be transported into neural cells for functional gene silencing or gene recombination.

Physicochemical Properties

CAS #	2739805-63-9
Appearance	Colorless to light yellow ointment
Density	1.124±0.06 g/cm3(Predicted)
Boiling Point	780.1±60.0 °C(Predicted)
LogP	0
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	A lipidoid with a tryptamine head group and a hydrophobic tail group with 12 carbon atoms is represented by the symbol NT1-O12B [1].
ln Vivo	Using a process akin to DiR encapsulation, it encapsulates AmB in pure NT1-lipoids (i.e., NT1-O12B, NT1-O14B, NT1-O16B, and NT1-O18B). Among all NT-lipoids, NT1-O12B exhibits the highest DiR fluorescence intensity, making it a dopant that improves brain delivery. The BBB-impermeable lipidoid PBA-Q76-O16B can be doped with NT1-O12B to produce an AmB formulation that is able to pass through the BBB. By using this technique, AmB concentrations in brain tissue reached 300 ng/g (AmB/tissue) less than 24 hours after AmB (5 mg/kg) was given intravenously, with a delivery efficiency of roughly 0.135% of the dose that was injected [1].
References	[1]. Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection. Sci Adv. 2020;6(30):eabb4429. Published 2020 Jul 24.

Solubility Data

Solubility (In Vitro)

DMSO: 200 mg/mL (280.45 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 5 mg/mL (7.01 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 5 mg/mL (7.01 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 5 mg/mL (7.01 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)